Does Vanzacaftor Tezacaftor And Deutivacaftor Interact with Strong Or Moderate Cyp3a Inducers?
Vanzacaftor Tezacaftor And Deutivacaftor and Strong Or Moderate Cyp3a Inducers have a major drug interaction according to U.S. FDA drug labeling data. Concomitant use is not recommended. CYP3A inducers decrease vanzacaftor, tezacaftor, and deutivacaftor exposure, which may reduce ALYFTREK effectiveness. The mechanism involves cyp3a induction decreases substrate exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Vanzacaftor Tezacaftor And Deutivacaftor Class
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Vanzacaftor Tezacaftor And Deutivacaftor and Strong Or Moderate Cyp3a Inducers occurs because cyp3a induction decreases substrate exposure. Clinically, this means concomitant use is not recommended. cyp3a inducers decrease vanzacaftor, tezacaftor, and deutivacaftor exposure, which may reduce alyftrek effectiveness. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Vanzacaftor Tezacaftor And Deutivacaftor and your doctor is considering prescribing Strong Or Moderate Cyp3a Inducers (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider